Welcome to: Rimonabant Information Source (rimonabant form1)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Acomplia should be once a day or as prescribed by your doctor. How can you buy Acomplia online? If you want to buy Acomplia online, but not sure whether you get it or not, go through an online consultation. This method of consultation is free of charge and without any obligation. You can buy Acomplia online in a very simple way. Everything you need to do is fill in the form of consultation with your data. Make sure you all correct and complete information so that a doctor can correct diagnosis. If you do not have serious medical conditions that could make Acomplia unsafe for you, then you get this medication without any problem. If you have certain medical conditions, in addition to others, such as impaired liver and kidney function, heart attack, depression and antidepressants on medication, pregnant or breastfeeding, etc., you can not get Acomplia.

Rimonabant Pricelist

Please wait while we load the price list
Rimonabant Acomplia is a wonder diet pill manufactured by Sanofi Aventis for weight loss treatment. Rimonabant Acomplia Zimulti has been approved by European Union in June 2006 and now has become the most popular treatment for weight loss in obese people. Rimonabant Acomplia is also known as magic drug as it helps for smoking cessation as well as heart diseases. Rimonabant Acomplia was made marketable in the UK and rest of Europe as result of a conformity made by 25-member European Union. Acomplia is an anti –obesity with Rimonabant, as its main constituent. Rimonabant was discovered and manufactured by a French pharmaceutical firm, Sanofi-Aventis. It works on the principle of targeting the CB-1 receptors, found in the Endo- cannabinoid (EC) system.

Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileRimonabant enhanced weight loss success, improved lipidsRimonabant weight loss sustained at 2 years The FDA was required to act on the rimonabant application by July 26, and the likely result would have been a "nonapprovable" letter. Although the committee's recommendations are not binding, the FDA generally follows the advice of its advisory panels. The advisory committee indicated during its meeting that it was willing to reconsider the issue after Sanofi completes the 17,000-patient Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO) in 2010; that study will have 5-year follow-up data on patients.